John M. McLaughlin

Pfizer, Inc.

235 East 42 Street

New York, NY 10017

United States

SCHOLARLY PAPERS

9

DOWNLOADS
Rank 6,237

SSRN RANKINGS

Top 6,237

in Total Papers Downloads

10,587

SSRN CITATIONS

2

CROSSREF CITATIONS

0

Scholarly Papers (9)

1.

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study

Number of pages: 40 Posted: 23 Aug 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 5,336 (2,368)

Abstract:

Loading...

2.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,104 (11,263)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

3.

Nationwide Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths

Number of pages: 24 Posted: 24 Mar 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Pfizer, Inc., Ministry of Health (Israel) - Public Health Services, Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Ministry of Health (Israel) - Information Technology Department, Ministry of Health (Israel) - Information Technology Department, Pfizer Pharmaceuticals Israel Ltd, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 1,628 (16,858)
Citation 1

Abstract:

Loading...

COVID-19, SARS-CoV-2, vaccine effectiveness, prevention, mRNA vaccines, pandemic, observational study, epidemiology

4.

Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel

Number of pages: 25 Posted: 13 May 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Yale UniversityMinistry of Health (Israel) - Public Health Services, Harvard T.H. Chan School of Public Health - Center for Communicable Disease Dynamics, Ministry of Health (Israel) - Public Health Services, Pfizer Pharmaceuticals Israel Ltd, Ministry of Health (Israel) - Information Technology Department, Ministry of Health (Israel) - Information Technology Department, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 448 (98,202)
Citation 1

Abstract:

Loading...

COVID-19, SARS-CoV-2, cases averted, impact, hospitalizations, deaths, Israel, model, public health, pandemic

5.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 381 (118,405)

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

6.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 361 (125,893)

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

7.

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel

Number of pages: 29 Posted: 13 Aug 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc., Ministry of Health (Israel), Israel Ministry of Health, Yale UniversityMinistry of Health (Israel) - Public Health Services, Sheba Medical Center - Central Virology Laboratory, Sheba Medical Center - Central Virology Laboratory, Sheba Medical Center - Central Virology Laboratory, Chaim Sheba Medical Center - Central Virology Laboratory, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc., Pfizer Pharmaceuticals Israel Ltd, Harvard T.H. Chan School of Public Health - Center for Communicable Disease Dynamics, Ministry of Health (Israel) - Public Health Services, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 175 (256,519)

Abstract:

Loading...

8.

Incidence of Community Acquired Lower Respiratory Tract Disease in Bristol, UK During the COVID-19 Pandemic

Number of pages: 31 Posted: 19 Apr 2022
University of Bristol - Population Health Sciences, University of Bristol - Department of Mathematics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University Hospitals Bristol NHS Foundation Trust - Clinical Research and Imaging Centre, University of Bristol - Academic Respiratory Unit, University of Bristol - Department of Population Health Sciences, University of Bristol - Population Health Sciences, University of Bristol - Department of Population Health Sciences, Pfizer, Inc., Pfizer, Inc., University of Bristol - Bristol Vaccine Centre, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., University of Bristol - Department of Population Health Sciences, University of Bristol - Academic Respiratory Unit, Pfizer Inc. - Medical and Scientific Affairs, University of Bristol - Engineering Mathematics and University of Bristol - Bristol Vaccine Centre
Downloads 102 (387,921)

Abstract:

Loading...

pneumonia, lower respiratory tract infection, cardiac failure, COVID-19, SARS-CoV-2

9.

County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States

Number of pages: 30 Posted: 20 Aug 2021
Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Harvard University - Center for Communicable Disease Dynamics and Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs
Downloads 52 (561,864)

Abstract:

Loading...